The PCA3 score may combined with traditional tools aid in identifying men with clinically insignificant prostate cancer, as shown by biopsy and RP pathological features including biopsy Epstein criteria, who could be candidates for active surveillance.
Treatment selection should be based on a combination of clinical and pathological variables.
If one wants to use a threshold point to guide treatment decisions in clinical practice, a PCA3 score threshold of 20 may have the highest utility for selecting men with clinically insignificant prostate cancer in whom active surveillance may be appropriate; a PCA3 score threshold of 50 may be used to identify men at high risk of harbouring significant prostate cancer who are candidates for RP. Although the association between the PCA3 score and prostate cancer aggressiveness needs further evaluation, the inclusion of the PCA3 score into patient management strategies may provide clinicians with another tool to more accurately determine the course of treatment.
2012-01-16
Eng.
BJU international
UZ Gasthuisberg, Leuven, Belgium, Austria. Hendrik.VanPoppel [at] uzleuven.be
BJU Int. 2012 Feb;109(3):360-6
© Galenicom 1999-2013